Market Outlook Despite the number of therapy options available, metastatic HR-positive/HER2-negative breast cancer remains incurable and is a major cause of mortality and morbidity in women…
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The availability of non-vitamin K…
Hormone receptor (HR)-positive/HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status,…
MARKET OUTLOOK The increase in oral oncolytics has fueled an increase in physician dispensing of drugs either from the office or from a pharmacy owned by the practice or hospital, as allowed by…
Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in understanding…
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in…
Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical…
The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting…
Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as…
Market Outlook: Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
Introduction: As one of the largest therapy markets in oncology, driven by a high incidence and long treatment durations, the treatment of metastatic HR+/HER2– breast cancer remains commercially…
Introduction: As one of the largest therapy markets in oncology, driven by a high incidence and long treatment durations, the treatment of metastatic HR+/HER2– breast cancer remains commercially…
Treatment of bladder cancer is influenced by a number of factors including disease stage and histology. The swift entry of immune checkpoint inhibitors has transformed the treatment algorithm for…